TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Target Temperature Management 33°C Versus 36°C After Out-of-hospital Cardiac Arrest, a Randomised, Parallel Groups, Assessor Blinded Clinical Trial
Brief Summary: Experimental studies and previous clinical trials suggest an improvement in mortality and neurological function with hypothermia after cardiac arrest. However, the accrued evidence is inconclusive and associated with risks of systematic error, design error and random error. Elevated body temperature after cardiac arrest is associated with a worse outcome. Previous trials did not treat elevated body temperature in the control groups. The optimal target temperature for post-resuscitation care is not known. The primary purpose with the TTM-trial is to evaluate if there are differences in all-cause mortality, neurological function and adverse events between a target temperature management at 33°C and 36°C for 24 hours following return of spontaneous circulation after cardiac arrest.


Options:
A: Arm Label: Normothermia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard care with early treatment of fever | Arm Label: Hypothermia; Type: EXPERIMENTAL; Interventions: Procedure: Targeted temperature management to 33°C | Intervention Type: PROCEDURE; Name: Targeted temperature management to 33°C; Assigned to Arm(s): Hypothermia | Intervention Type: PROCEDURE; Name: Standard care with early treatment of fever; Assigned to Arm(s): Normothermia
B: Arm Label: Target Temperature 33°C; Type: EXPERIMENTAL; Interventions: Procedure: Target Temperature 33°C | Arm Label: Target Temperature 36°C; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Target temperature 36°C | Intervention Type: PROCEDURE; Name: Target temperature 36°C; Assigned to Arm(s): Target Temperature 36°C | Intervention Type: PROCEDURE; Name: Target Temperature 33°C; Assigned to Arm(s): Target Temperature 33°C
C: Arm Label: Targeted controlled temperature between 32.5 and 33.5°C; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Targeted controlled temperature between 32.5 and 33.5°C, Procedure: Targeted controlled temperature between 36.5 and 37.5°C | Arm Label: Targeted controlled temperature between 36.5 and 37.5°C; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Targeted controlled temperature between 36.5 and 37.5°C | Intervention Type: PROCEDURE; Name: Targeted controlled temperature between 32.5 and 33.5°C; Assigned to Arm(s): Targeted controlled temperature between 32.5 and 33.5°C | Intervention Type: PROCEDURE; Name: Targeted controlled temperature between 36.5 and 37.5°C; Assigned to Arm(s): Targeted controlled temperature between 32.5 and 33.5°C, Targeted controlled temperature between 36.5 and 37.5°C
D: Arm Label: control treatment; Type: NO_INTERVENTION; Interventions: Other: Rapid infusion of 2 liters of 4oC normal saline, Drug: Rapid infusion of cold normal saline | Intervention Type: OTHER; Name: Rapid infusion of 2 liters of 4oC normal saline; Assigned to Arm(s): control treatment | Intervention Type: DRUG; Name: Rapid infusion of cold normal saline; Assigned to Arm(s): control treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Target Temperature Management 33°C Versus 36°C After Out-of-hospital Cardiac Arrest, a Randomised, Parallel Groups, Assessor Blinded Clinical Trial
Brief Summary: Experimental studies and previous clinical trials suggest an improvement in mortality and neurological function with hypothermia after cardiac arrest. However, the accrued evidence is inconclusive and associated with risks of systematic error, design error and random error. Elevated body temperature after cardiac arrest is associated with a worse outcome. Previous trials did not treat elevated body temperature in the control groups. The optimal target temperature for post-resuscitation care is not known. The primary purpose with the TTM-trial is to evaluate if there are differences in all-cause mortality, neurological function and adverse events between a target temperature management at 33°C and 36°C for 24 hours following return of spontaneous circulation after cardiac arrest.


Options:
A: Arm Label: Hyperinvasive arm; Type: EXPERIMENTAL; Interventions: Device: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS | Arm Label: Standard arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS; Assigned to Arm(s): Hyperinvasive arm | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard arm
B: Arm Label: control treatment; Type: NO_INTERVENTION; Interventions: Other: Rapid infusion of 2 liters of 4oC normal saline, Drug: Rapid infusion of cold normal saline | Intervention Type: OTHER; Name: Rapid infusion of 2 liters of 4oC normal saline; Assigned to Arm(s): control treatment | Intervention Type: DRUG; Name: Rapid infusion of cold normal saline; Assigned to Arm(s): control treatment
C: Arm Label: RhinoChill; Type: EXPERIMENTAL; Interventions: Device: RhinoChill | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DEVICE; Name: RhinoChill; Assigned to Arm(s): RhinoChill | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Target Temperature 33°C; Type: EXPERIMENTAL; Interventions: Procedure: Target Temperature 33°C | Arm Label: Target Temperature 36°C; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Target temperature 36°C | Intervention Type: PROCEDURE; Name: Target temperature 36°C; Assigned to Arm(s): Target Temperature 36°C | Intervention Type: PROCEDURE; Name: Target Temperature 33°C; Assigned to Arm(s): Target Temperature 33°C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy
Brief Summary: This study is designed to assess the safety profile and the efficacy of cardiac repair cells (CRCs) administered via catheter in treating patients with dilated cardiomyopathy (DCM).


Options:
A: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group
B: Arm Label: Ixmyelocel-T; Type: EXPERIMENTAL; Interventions: Biological: Ixmyelocel-T | Arm Label: Vehicle Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Vehicle Control | Intervention Type: BIOLOGICAL; Name: Ixmyelocel-T; Assigned to Arm(s): Ixmyelocel-T | Intervention Type: OTHER; Name: Vehicle Control; Assigned to Arm(s): Vehicle Control
C: Arm Label: Optimal Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: optimal therapy for cardiaca failure | Arm Label: cell therapy; Type: EXPERIMENTAL; Interventions: Procedure: cell | Intervention Type: DRUG; Name: optimal therapy for cardiaca failure; Assigned to Arm(s): Optimal Therapy | Intervention Type: PROCEDURE; Name: cell; Assigned to Arm(s): cell therapy
D: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Applying Mindfulness-Based Cognitive Therapy to Treatment Resistant Depression
Brief Summary: This study is a randomized, controlled trial of Mindfulness-Based Cognitive Therapy (MBCT) versus Health-Enhancement Program (HEP) for patients with treatment-resistant major depressive disorder (MDD). Both arms of the study will continue to receive the standard medication management treatment as usual (TAU) throughout the study. MBCT is a new technique that has been found to be effective for prevention of relapse in individuals in complete recovery from depression. MBCT is a group-based, 8-week intervention that uses mindfulness meditation as its core therapeutic ingredient. It teaches people to have a different relationship to depressive thoughts and feelings. This study will use an active condition called the Health Enhancement Program (HEP) which was specifically developed to serve as a comparison condition for mindfulness interventions. HEP has been shown to decrease global stress levels and to increase perceived health. Stress has been considered a contributor to depression. One hundred and seventy four patients with MDD who have failed two or more adequate antidepressant trials will be identified and randomly assigned to one of two groups: MBCT+TAU or HEP+TAU. All patients who enroll in the study will undergo follow-up assessments at 3, 6, 9 and 12 months following the intervention. A supplemental portion of the study will enroll 88 patients to undergo functional magnetic resonance imagining (fMRI) scans immediately before and after treatment to better understand the neural pathways implicated in depression and those that may be affected through treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Enhancement Program and medication management | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Health Enhancement Program and medication management; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Control with depression course (CWD); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram, Behavioral: Interpersonal Psychotherapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram, Behavioral: Clinical Monitoring | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Clinical Monitoring; Assigned to Arm(s): 2
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Specialist Mood Disorders Team | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialist Mood Disorders Team; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of GSK Biologicals' IPV (Poliorix™) in Infants
Brief Summary: The purpose of the study is to evaluate the immunogenicity and safety of Poliorix™ when administered to healthy Chinese infants at 2, 3 and 4 months of age.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group B
B: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group
C: Intervention Type: BIOLOGICAL; Name: Inactivated Polio Vaccine given at an accelerated schedule; Assigned to Arm(s): N/A
D: Arm Label: Kinrix + M-M-R II + Varivax; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Arm Label: Kinrix + M-M-R II -> Varivax; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals'Kinrix®, Biological: Merck and Company's MMRII, Biological: Merck and Company's Varivax | Intervention Type: BIOLOGICAL; Name: GSK Biologicals'Kinrix®; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's MMRII; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax | Intervention Type: BIOLOGICAL; Name: Merck and Company's Varivax; Assigned to Arm(s): Kinrix + M-M-R II + Varivax, Kinrix + M-M-R II -> Varivax

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The GP's Role in Cancer Rehabilitation: a Randomised, Controlled Study.
Brief Summary: The aim of this study is to investigate the impact of a joint effort towards intensifying the collaboration and communication between hospital and general practice.


Options:
A: Intervention Type: BEHAVIORAL; Name: Community Interlink Program; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Intervention | Arm Label: Attention; Type: EXPERIMENTAL; Interventions: Other: Attention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Attention; Assigned to Arm(s): Attention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Patient interview and communication to GP from hospital; Type: EXPERIMENTAL; Interventions: Behavioral: Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs | Arm Label: Control group: Usual practice, no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs; Assigned to Arm(s): Patient interview and communication to GP from hospital
D: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)
Brief Summary: Blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. Retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. There are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.This study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion with Red Blood Cells, Biological: 1 unit of donated red blood cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1 unit of donated red blood cells | Intervention Type: PROCEDURE; Name: Transfusion with Red Blood Cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 2
B: Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Procedure: Restrictive transfusion, Biological: red blood transfusion | Arm Label: Liberal transfusion strategy; Type: EXPERIMENTAL; Interventions: Procedure: Liberal transfusion, Biological: red blood transfusion | Intervention Type: PROCEDURE; Name: Restrictive transfusion; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: PROCEDURE; Name: Liberal transfusion; Assigned to Arm(s): Liberal transfusion strategy | Intervention Type: BIOLOGICAL; Name: red blood transfusion; Assigned to Arm(s): Liberal transfusion strategy, Restrictive transfusion strategy
C: Arm Label: Restrictive; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion | Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion | Intervention Type: PROCEDURE; Name: Blood Transfusion; Assigned to Arm(s): Liberal, Restrictive
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)
Brief Summary: Blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. Retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. There are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.This study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.


Options:
A: Arm Label: Thromboelastography (TEG) level; Type: EXPERIMENTAL; Interventions: Biological: Fresh Frozen Plasma, Biological: Platelets Concentrate, Biological: Cryo Precitipitate | Arm Label: Coagulation Profile; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh Frozen Plasma, Biological: Platelets Concentrate, Biological: Cryo Precitipitate | Intervention Type: BIOLOGICAL; Name: Fresh Frozen Plasma; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level | Intervention Type: BIOLOGICAL; Name: Platelets Concentrate; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level | Intervention Type: BIOLOGICAL; Name: Cryo Precitipitate; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level
B: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy
C: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
D: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)
Brief Summary: Blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. Retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. There are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.This study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.


Options:
A: Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Intervention Type: BIOLOGICAL; Name: Administration of Red Cell; Assigned to Arm(s): Liberal, Restrictive
B: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
C: Arm Label: Restrictive RBC Transfusion Group; Type: EXPERIMENTAL; Interventions: Biological: Restrictive RBC Transfusion | Arm Label: Liberal RBC Transfusion Group; Type: EXPERIMENTAL; Interventions: Biological: Liberal RBC Transfusion | Intervention Type: BIOLOGICAL; Name: Restrictive RBC Transfusion; Assigned to Arm(s): Restrictive RBC Transfusion Group | Intervention Type: BIOLOGICAL; Name: Liberal RBC Transfusion; Assigned to Arm(s): Liberal RBC Transfusion Group
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Intervention Type: BIOLOGICAL; Name: Red Blood Cell Transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive Transfusion Strategy

Answer: B